VCBeat Health
Contact Us
Home
China Healthcare Select
Insights
MNC China Lens
Vertical Industries
Services
Partnership Development
Market Entry Advisory
Ecosystem Engagement Advisory
About VCBeat
Why VCBeat
Log In
Home
NMPA Accepts InnoCare's Orelabrutinib NDA for Immune Thrombocytopenia (ITP)
NMPA Accepts InnoCare's Orelabrutinib NDA for Immune Thrombocytopenia (ITP)
May 28, 2026 16:23 CST Updated 18:18
Share:
InnoCare
Innovative Drug Developer
